EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Désirée van der Heijde, Daniel Aletaha et al.|Annals of the Rheumatic Diseases|2020Cited by 2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Désirée van der Heijde, Robert Landewé et al.|Annals of the Rheumatic Diseases|2022Cited by 1.9k
2022 updateJosef S Smolen, Josef S. Smolen, Robert Landewé et al.|Radboud Repository (Radboud University)|2010Cited by 1.6k
The apoptosis-1/Fas protein in human systemic lupus erythematosus.Eduardo Mysler, Keith B. Elkon, P Bini et al.|Journal of Clinical Investigation|1994Cited by 201
Levels of soluble fas/APO‐1 /CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritisEckart Knipping, Keith B. Elkon, Peter H. Krammer et al.|Arthritis & Rheumatism|1995Cited by 82